

# Global Targeted Radionuclide Drug Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G1650F73B5DBEN.html>

Date: July 2023

Pages: 125

Price: US\$ 4,480.00 (Single User License)

ID: G1650F73B5DBEN

## Abstracts

The global Targeted Radionuclide Drug market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Targeted Radionuclide Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Targeted Radionuclide Drug, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted Radionuclide Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Targeted Radionuclide Drug total market, 2018-2029, (USD Million)

Global Targeted Radionuclide Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Targeted Radionuclide Drug total market, key domestic companies and share, (USD Million)

Global Targeted Radionuclide Drug revenue by player and market share 2018-2023, (USD Million)

Global Targeted Radionuclide Drug total market by Type, CAGR, 2018-2029, (USD

Million)

Global Targeted Radionuclide Drug total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Targeted Radionuclide Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Fusion Pharmaceuticals and RadioMedix, Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Targeted Radionuclide Drug market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Targeted Radionuclide Drug Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

## Global Targeted Radionuclide Drug Market, Segmentation by Type

Medicine

Inhibitor

## Global Targeted Radionuclide Drug Market, Segmentation by Application

Tumors

Thyroid

Others

## Companies Profiled:

POINT Biopharma

Telix

ITM AG

Bayer AG

Novartis

Lantheus

Curium Pharma

Fusion Pharmaceuticals

RadioMedix, Inc.

Convergent Therapeutics

IONETIX

Clarity Pharmaceuticals

RayzeBio, Inc

AmbioPharm

Bracco Imaging

Navidea

China Isotope & Radiation Corporation

Yantai Dongcheng

Grand Pharma

Hengrui Medicine

Yunnan Baiyao Group

SmartNuclide Biopharma

Sinotau

Hexin Pharmaceutical

## Key Questions Answered

1. How big is the global Targeted Radionuclide Drug market?
2. What is the demand of the global Targeted Radionuclide Drug market?
3. What is the year over year growth of the global Targeted Radionuclide Drug market?

4. What is the total value of the global Targeted Radionuclide Drug market?
5. Who are the major players in the global Targeted Radionuclide Drug market?
6. What are the growth factors driving the market demand?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 Targeted Radionuclide Drug Introduction
- 1.2 World Targeted Radionuclide Drug Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Targeted Radionuclide Drug Total Market by Region (by Headquarter Location)
  - 1.3.1 World Targeted Radionuclide Drug Market Size by Region (2018-2029), (by Headquarter Location)
  - 1.3.2 United States Targeted Radionuclide Drug Market Size (2018-2029)
  - 1.3.3 China Targeted Radionuclide Drug Market Size (2018-2029)
  - 1.3.4 Europe Targeted Radionuclide Drug Market Size (2018-2029)
  - 1.3.5 Japan Targeted Radionuclide Drug Market Size (2018-2029)
  - 1.3.6 South Korea Targeted Radionuclide Drug Market Size (2018-2029)
  - 1.3.7 ASEAN Targeted Radionuclide Drug Market Size (2018-2029)
  - 1.3.8 India Targeted Radionuclide Drug Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Targeted Radionuclide Drug Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Targeted Radionuclide Drug Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
  - 1.5.1 Influence of COVID-19
  - 1.5.2 Influence of Russia-Ukraine War

### 2 DEMAND SUMMARY

- 2.1 World Targeted Radionuclide Drug Consumption Value (2018-2029)
- 2.2 World Targeted Radionuclide Drug Consumption Value by Region
  - 2.2.1 World Targeted Radionuclide Drug Consumption Value by Region (2018-2023)
  - 2.2.2 World Targeted Radionuclide Drug Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Targeted Radionuclide Drug Consumption Value (2018-2029)
- 2.4 China Targeted Radionuclide Drug Consumption Value (2018-2029)
- 2.5 Europe Targeted Radionuclide Drug Consumption Value (2018-2029)
- 2.6 Japan Targeted Radionuclide Drug Consumption Value (2018-2029)
- 2.7 South Korea Targeted Radionuclide Drug Consumption Value (2018-2029)
- 2.8 ASEAN Targeted Radionuclide Drug Consumption Value (2018-2029)
- 2.9 India Targeted Radionuclide Drug Consumption Value (2018-2029)

### **3 WORLD TARGETED RADIONUCLIDE DRUG COMPANIES COMPETITIVE ANALYSIS**

- 3.1 World Targeted Radionuclide Drug Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
  - 3.2.1 Global Targeted Radionuclide Drug Industry Rank of Major Players
  - 3.2.2 Global Concentration Ratios (CR4) for Targeted Radionuclide Drug in 2022
  - 3.2.3 Global Concentration Ratios (CR8) for Targeted Radionuclide Drug in 2022
- 3.3 Targeted Radionuclide Drug Company Evaluation Quadrant
- 3.4 Targeted Radionuclide Drug Market: Overall Company Footprint Analysis
  - 3.4.1 Targeted Radionuclide Drug Market: Region Footprint
  - 3.4.2 Targeted Radionuclide Drug Market: Company Product Type Footprint
  - 3.4.3 Targeted Radionuclide Drug Market: Company Product Application Footprint
- 3.5 Competitive Environment
  - 3.5.1 Historical Structure of the Industry
  - 3.5.2 Barriers of Market Entry
  - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

### **4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)**

- 4.1 United States VS China: Targeted Radionuclide Drug Revenue Comparison (by Headquarter Location)
  - 4.1.1 United States VS China: Targeted Radionuclide Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
  - 4.1.2 United States VS China: Targeted Radionuclide Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Targeted Radionuclide Drug Consumption Value Comparison
  - 4.2.1 United States VS China: Targeted Radionuclide Drug Consumption Value Comparison (2018 & 2022 & 2029)
  - 4.2.2 United States VS China: Targeted Radionuclide Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Targeted Radionuclide Drug Companies and Market Share, 2018-2023
  - 4.3.1 United States Based Targeted Radionuclide Drug Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Targeted Radionuclide Drug Revenue, (2018-2023)

4.4 China Based Companies Targeted Radionuclide Drug Revenue and Market Share, 2018-2023

4.4.1 China Based Targeted Radionuclide Drug Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Targeted Radionuclide Drug Revenue, (2018-2023)

4.5 Rest of World Based Targeted Radionuclide Drug Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Targeted Radionuclide Drug Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Targeted Radionuclide Drug Revenue, (2018-2023)

## **5 MARKET ANALYSIS BY TYPE**

5.1 World Targeted Radionuclide Drug Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Medicine

5.2.2 Inhibitor

5.3 Market Segment by Type

5.3.1 World Targeted Radionuclide Drug Market Size by Type (2018-2023)

5.3.2 World Targeted Radionuclide Drug Market Size by Type (2024-2029)

5.3.3 World Targeted Radionuclide Drug Market Size Market Share by Type (2018-2029)

## **6 MARKET ANALYSIS BY APPLICATION**

6.1 World Targeted Radionuclide Drug Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Tumors

6.2.2 Thyroid

6.2.3 Others

6.3 Market Segment by Application

6.3.1 World Targeted Radionuclide Drug Market Size by Application (2018-2023)

6.3.2 World Targeted Radionuclide Drug Market Size by Application (2024-2029)

6.3.3 World Targeted Radionuclide Drug Market Size by Application (2018-2029)



## 7 COMPANY PROFILES

### 7.1 POINT Biopharma

7.1.1 POINT Biopharma Details

7.1.2 POINT Biopharma Major Business

7.1.3 POINT Biopharma Targeted Radionuclide Drug Product and Services

7.1.4 POINT Biopharma Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 POINT Biopharma Recent Developments/Updates

7.1.6 POINT Biopharma Competitive Strengths & Weaknesses

### 7.2 Telix

7.2.1 Telix Details

7.2.2 Telix Major Business

7.2.3 Telix Targeted Radionuclide Drug Product and Services

7.2.4 Telix Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 Telix Recent Developments/Updates

7.2.6 Telix Competitive Strengths & Weaknesses

### 7.3 ITM AG

7.3.1 ITM AG Details

7.3.2 ITM AG Major Business

7.3.3 ITM AG Targeted Radionuclide Drug Product and Services

7.3.4 ITM AG Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 ITM AG Recent Developments/Updates

7.3.6 ITM AG Competitive Strengths & Weaknesses

### 7.4 Bayer AG

7.4.1 Bayer AG Details

7.4.2 Bayer AG Major Business

7.4.3 Bayer AG Targeted Radionuclide Drug Product and Services

7.4.4 Bayer AG Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 Bayer AG Recent Developments/Updates

7.4.6 Bayer AG Competitive Strengths & Weaknesses

### 7.5 Novartis

7.5.1 Novartis Details

7.5.2 Novartis Major Business

7.5.3 Novartis Targeted Radionuclide Drug Product and Services

- 7.5.4 Novartis Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
- 7.5.5 Novartis Recent Developments/Updates
- 7.5.6 Novartis Competitive Strengths & Weaknesses
- 7.6 Lantheus
  - 7.6.1 Lantheus Details
  - 7.6.2 Lantheus Major Business
  - 7.6.3 Lantheus Targeted Radionuclide Drug Product and Services
  - 7.6.4 Lantheus Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.6.5 Lantheus Recent Developments/Updates
  - 7.6.6 Lantheus Competitive Strengths & Weaknesses
- 7.7 Curium Pharma
  - 7.7.1 Curium Pharma Details
  - 7.7.2 Curium Pharma Major Business
  - 7.7.3 Curium Pharma Targeted Radionuclide Drug Product and Services
  - 7.7.4 Curium Pharma Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.7.5 Curium Pharma Recent Developments/Updates
  - 7.7.6 Curium Pharma Competitive Strengths & Weaknesses
- 7.8 Fusion Pharmaceuticals
  - 7.8.1 Fusion Pharmaceuticals Details
  - 7.8.2 Fusion Pharmaceuticals Major Business
  - 7.8.3 Fusion Pharmaceuticals Targeted Radionuclide Drug Product and Services
  - 7.8.4 Fusion Pharmaceuticals Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.8.5 Fusion Pharmaceuticals Recent Developments/Updates
  - 7.8.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
- 7.9 RadioMedix, Inc.
  - 7.9.1 RadioMedix, Inc. Details
  - 7.9.2 RadioMedix, Inc. Major Business
  - 7.9.3 RadioMedix, Inc. Targeted Radionuclide Drug Product and Services
  - 7.9.4 RadioMedix, Inc. Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.9.5 RadioMedix, Inc. Recent Developments/Updates
  - 7.9.6 RadioMedix, Inc. Competitive Strengths & Weaknesses
- 7.10 Convergent Therapeutics
  - 7.10.1 Convergent Therapeutics Details
  - 7.10.2 Convergent Therapeutics Major Business

- 7.10.3 Convergent Therapeutics Targeted Radionuclide Drug Product and Services
- 7.10.4 Convergent Therapeutics Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
- 7.10.5 Convergent Therapeutics Recent Developments/Updates
- 7.10.6 Convergent Therapeutics Competitive Strengths & Weaknesses
- 7.11 IONETIX
  - 7.11.1 IONETIX Details
  - 7.11.2 IONETIX Major Business
  - 7.11.3 IONETIX Targeted Radionuclide Drug Product and Services
  - 7.11.4 IONETIX Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.11.5 IONETIX Recent Developments/Updates
  - 7.11.6 IONETIX Competitive Strengths & Weaknesses
- 7.12 Clarity Pharmaceuticals
  - 7.12.1 Clarity Pharmaceuticals Details
  - 7.12.2 Clarity Pharmaceuticals Major Business
  - 7.12.3 Clarity Pharmaceuticals Targeted Radionuclide Drug Product and Services
  - 7.12.4 Clarity Pharmaceuticals Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.12.5 Clarity Pharmaceuticals Recent Developments/Updates
  - 7.12.6 Clarity Pharmaceuticals Competitive Strengths & Weaknesses
- 7.13 RayzeBio, Inc
  - 7.13.1 RayzeBio, Inc Details
  - 7.13.2 RayzeBio, Inc Major Business
  - 7.13.3 RayzeBio, Inc Targeted Radionuclide Drug Product and Services
  - 7.13.4 RayzeBio, Inc Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.13.5 RayzeBio, Inc Recent Developments/Updates
  - 7.13.6 RayzeBio, Inc Competitive Strengths & Weaknesses
- 7.14 AmbioPharm
  - 7.14.1 AmbioPharm Details
  - 7.14.2 AmbioPharm Major Business
  - 7.14.3 AmbioPharm Targeted Radionuclide Drug Product and Services
  - 7.14.4 AmbioPharm Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.14.5 AmbioPharm Recent Developments/Updates
  - 7.14.6 AmbioPharm Competitive Strengths & Weaknesses
- 7.15 Bracco Imaging
  - 7.15.1 Bracco Imaging Details

- 7.15.2 Bracco Imaging Major Business
- 7.15.3 Bracco Imaging Targeted Radionuclide Drug Product and Services
- 7.15.4 Bracco Imaging Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
- 7.15.5 Bracco Imaging Recent Developments/Updates
- 7.15.6 Bracco Imaging Competitive Strengths & Weaknesses
- 7.16 Navidea
  - 7.16.1 Navidea Details
  - 7.16.2 Navidea Major Business
  - 7.16.3 Navidea Targeted Radionuclide Drug Product and Services
  - 7.16.4 Navidea Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.16.5 Navidea Recent Developments/Updates
  - 7.16.6 Navidea Competitive Strengths & Weaknesses
- 7.17 China Isotope & Radiation Corporation
  - 7.17.1 China Isotope & Radiation Corporation Details
  - 7.17.2 China Isotope & Radiation Corporation Major Business
  - 7.17.3 China Isotope & Radiation Corporation Targeted Radionuclide Drug Product and Services
  - 7.17.4 China Isotope & Radiation Corporation Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.17.5 China Isotope & Radiation Corporation Recent Developments/Updates
  - 7.17.6 China Isotope & Radiation Corporation Competitive Strengths & Weaknesses
- 7.18 Yantai Dongcheng
  - 7.18.1 Yantai Dongcheng Details
  - 7.18.2 Yantai Dongcheng Major Business
  - 7.18.3 Yantai Dongcheng Targeted Radionuclide Drug Product and Services
  - 7.18.4 Yantai Dongcheng Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.18.5 Yantai Dongcheng Recent Developments/Updates
  - 7.18.6 Yantai Dongcheng Competitive Strengths & Weaknesses
- 7.19 Grand Pharma
  - 7.19.1 Grand Pharma Details
  - 7.19.2 Grand Pharma Major Business
  - 7.19.3 Grand Pharma Targeted Radionuclide Drug Product and Services
  - 7.19.4 Grand Pharma Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)
  - 7.19.5 Grand Pharma Recent Developments/Updates
  - 7.19.6 Grand Pharma Competitive Strengths & Weaknesses

## 7.20 Hengrui Medicine

### 7.20.1 Hengrui Medicine Details

### 7.20.2 Hengrui Medicine Major Business

### 7.20.3 Hengrui Medicine Targeted Radionuclide Drug Product and Services

### 7.20.4 Hengrui Medicine Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)

### 7.20.5 Hengrui Medicine Recent Developments/Updates

### 7.20.6 Hengrui Medicine Competitive Strengths & Weaknesses

## 7.21 Yunnan Baiyao Group

### 7.21.1 Yunnan Baiyao Group Details

### 7.21.2 Yunnan Baiyao Group Major Business

### 7.21.3 Yunnan Baiyao Group Targeted Radionuclide Drug Product and Services

### 7.21.4 Yunnan Baiyao Group Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)

### 7.21.5 Yunnan Baiyao Group Recent Developments/Updates

### 7.21.6 Yunnan Baiyao Group Competitive Strengths & Weaknesses

## 7.22 SmartNuclide Biopharma

### 7.22.1 SmartNuclide Biopharma Details

### 7.22.2 SmartNuclide Biopharma Major Business

### 7.22.3 SmartNuclide Biopharma Targeted Radionuclide Drug Product and Services

### 7.22.4 SmartNuclide Biopharma Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)

### 7.22.5 SmartNuclide Biopharma Recent Developments/Updates

### 7.22.6 SmartNuclide Biopharma Competitive Strengths & Weaknesses

## 7.23 Sinotau

### 7.23.1 Sinotau Details

### 7.23.2 Sinotau Major Business

### 7.23.3 Sinotau Targeted Radionuclide Drug Product and Services

### 7.23.4 Sinotau Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)

### 7.23.5 Sinotau Recent Developments/Updates

### 7.23.6 Sinotau Competitive Strengths & Weaknesses

## 7.24 Hexin Pharmaceutical

### 7.24.1 Hexin Pharmaceutical Details

### 7.24.2 Hexin Pharmaceutical Major Business

### 7.24.3 Hexin Pharmaceutical Targeted Radionuclide Drug Product and Services

### 7.24.4 Hexin Pharmaceutical Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023)

### 7.24.5 Hexin Pharmaceutical Recent Developments/Updates

#### 7.24.6 Hexin Pharmaceutical Competitive Strengths & Weaknesses

### **8 INDUSTRY CHAIN ANALYSIS**

8.1 Targeted Radionuclide Drug Industry Chain

8.2 Targeted Radionuclide Drug Upstream Analysis

8.3 Targeted Radionuclide Drug Midstream Analysis

8.4 Targeted Radionuclide Drug Downstream Analysis

### **9 RESEARCH FINDINGS AND CONCLUSION**

### **10 APPENDIX**

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer



## List Of Tables

### LIST OF TABLES

Table 1. World Targeted Radionuclide Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Targeted Radionuclide Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Targeted Radionuclide Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Targeted Radionuclide Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Targeted Radionuclide Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Targeted Radionuclide Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Targeted Radionuclide Drug Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Targeted Radionuclide Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Targeted Radionuclide Drug Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Targeted Radionuclide Drug Players in 2022

Table 12. World Targeted Radionuclide Drug Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Targeted Radionuclide Drug Company Evaluation Quadrant

Table 14. Head Office of Key Targeted Radionuclide Drug Player

Table 15. Targeted Radionuclide Drug Market: Company Product Type Footprint

Table 16. Targeted Radionuclide Drug Market: Company Product Application Footprint

Table 17. Targeted Radionuclide Drug Mergers & Acquisitions Activity

Table 18. United States VS China Targeted Radionuclide Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Targeted Radionuclide Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Targeted Radionuclide Drug Companies, Headquarters (States, Country)

Table 21. United States Based Companies Targeted Radionuclide Drug Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Targeted Radionuclide Drug Revenue Market Share (2018-2023)

Table 23. China Based Targeted Radionuclide Drug Companies, Headquarters (Province, Country)

Table 24. China Based Companies Targeted Radionuclide Drug Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Targeted Radionuclide Drug Revenue Market Share (2018-2023)

Table 26. Rest of World Based Targeted Radionuclide Drug Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Targeted Radionuclide Drug Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Targeted Radionuclide Drug Revenue Market Share (2018-2023)

Table 29. World Targeted Radionuclide Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Targeted Radionuclide Drug Market Size by Type (2018-2023) & (USD Million)

Table 31. World Targeted Radionuclide Drug Market Size by Type (2024-2029) & (USD Million)

Table 32. World Targeted Radionuclide Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Targeted Radionuclide Drug Market Size by Application (2018-2023) & (USD Million)

Table 34. World Targeted Radionuclide Drug Market Size by Application (2024-2029) & (USD Million)

Table 35. POINT Biopharma Basic Information, Area Served and Competitors

Table 36. POINT Biopharma Major Business

Table 37. POINT Biopharma Targeted Radionuclide Drug Product and Services

Table 38. POINT Biopharma Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. POINT Biopharma Recent Developments/Updates

Table 40. POINT Biopharma Competitive Strengths & Weaknesses

Table 41. Telix Basic Information, Area Served and Competitors

Table 42. Telix Major Business

Table 43. Telix Targeted Radionuclide Drug Product and Services

Table 44. Telix Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. Telix Recent Developments/Updates



Table 46. Telix Competitive Strengths & Weaknesses
Table 47. ITM AG Basic Information, Area Served and Competitors
Table 48. ITM AG Major Business
Table 49. ITM AG Targeted Radionuclide Drug Product and Services
Table 50. ITM AG Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. ITM AG Recent Developments/Updates
Table 52. ITM AG Competitive Strengths & Weaknesses
Table 53. Bayer AG Basic Information, Area Served and Competitors
Table 54. Bayer AG Major Business
Table 55. Bayer AG Targeted Radionuclide Drug Product and Services
Table 56. Bayer AG Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Bayer AG Recent Developments/Updates
Table 58. Bayer AG Competitive Strengths & Weaknesses
Table 59. Novartis Basic Information, Area Served and Competitors
Table 60. Novartis Major Business
Table 61. Novartis Targeted Radionuclide Drug Product and Services
Table 62. Novartis Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Novartis Recent Developments/Updates
Table 64. Novartis Competitive Strengths & Weaknesses
Table 65. Lantheus Basic Information, Area Served and Competitors
Table 66. Lantheus Major Business
Table 67. Lantheus Targeted Radionuclide Drug Product and Services
Table 68. Lantheus Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Lantheus Recent Developments/Updates
Table 70. Lantheus Competitive Strengths & Weaknesses
Table 71. Curium Pharma Basic Information, Area Served and Competitors
Table 72. Curium Pharma Major Business
Table 73. Curium Pharma Targeted Radionuclide Drug Product and Services
Table 74. Curium Pharma Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Curium Pharma Recent Developments/Updates
Table 76. Curium Pharma Competitive Strengths & Weaknesses
Table 77. Fusion Pharmaceuticals Basic Information, Area Served and Competitors
Table 78. Fusion Pharmaceuticals Major Business
Table 79. Fusion Pharmaceuticals Targeted Radionuclide Drug Product and Services

Table 80. Fusion Pharmaceuticals Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 81. Fusion Pharmaceuticals Recent Developments/Updates

Table 82. Fusion Pharmaceuticals Competitive Strengths & Weaknesses

Table 83. RadioMedix, Inc. Basic Information, Area Served and Competitors

Table 84. RadioMedix, Inc. Major Business

Table 85. RadioMedix, Inc. Targeted Radionuclide Drug Product and Services

Table 86. RadioMedix, Inc. Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 87. RadioMedix, Inc. Recent Developments/Updates

Table 88. RadioMedix, Inc. Competitive Strengths & Weaknesses

Table 89. Convergent Therapeutics Basic Information, Area Served and Competitors

Table 90. Convergent Therapeutics Major Business

Table 91. Convergent Therapeutics Targeted Radionuclide Drug Product and Services

Table 92. Convergent Therapeutics Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 93. Convergent Therapeutics Recent Developments/Updates

Table 94. Convergent Therapeutics Competitive Strengths & Weaknesses

Table 95. IONETIX Basic Information, Area Served and Competitors

Table 96. IONETIX Major Business

Table 97. IONETIX Targeted Radionuclide Drug Product and Services

Table 98. IONETIX Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 99. IONETIX Recent Developments/Updates

Table 100. IONETIX Competitive Strengths & Weaknesses

Table 101. Clarity Pharmaceuticals Basic Information, Area Served and Competitors

Table 102. Clarity Pharmaceuticals Major Business

Table 103. Clarity Pharmaceuticals Targeted Radionuclide Drug Product and Services

Table 104. Clarity Pharmaceuticals Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 105. Clarity Pharmaceuticals Recent Developments/Updates

Table 106. Clarity Pharmaceuticals Competitive Strengths & Weaknesses

Table 107. RayzeBio, Inc Basic Information, Area Served and Competitors

Table 108. RayzeBio, Inc Major Business

Table 109. RayzeBio, Inc Targeted Radionuclide Drug Product and Services

Table 110. RayzeBio, Inc Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 111. RayzeBio, Inc Recent Developments/Updates

Table 112. RayzeBio, Inc Competitive Strengths & Weaknesses

Table 113. AmbioPharm Basic Information, Area Served and Competitors
Table 114. AmbioPharm Major Business
Table 115. AmbioPharm Targeted Radionuclide Drug Product and Services
Table 116. AmbioPharm Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. AmbioPharm Recent Developments/Updates
Table 118. AmbioPharm Competitive Strengths & Weaknesses
Table 119. Bracco Imaging Basic Information, Area Served and Competitors
Table 120. Bracco Imaging Major Business
Table 121. Bracco Imaging Targeted Radionuclide Drug Product and Services
Table 122. Bracco Imaging Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Bracco Imaging Recent Developments/Updates
Table 124. Bracco Imaging Competitive Strengths & Weaknesses
Table 125. Navidea Basic Information, Area Served and Competitors
Table 126. Navidea Major Business
Table 127. Navidea Targeted Radionuclide Drug Product and Services
Table 128. Navidea Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Navidea Recent Developments/Updates
Table 130. Navidea Competitive Strengths & Weaknesses
Table 131. China Isotope & Radiation Corporation Basic Information, Area Served and Competitors
Table 132. China Isotope & Radiation Corporation Major Business
Table 133. China Isotope & Radiation Corporation Targeted Radionuclide Drug Product and Services
Table 134. China Isotope & Radiation Corporation Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. China Isotope & Radiation Corporation Recent Developments/Updates
Table 136. China Isotope & Radiation Corporation Competitive Strengths & Weaknesses
Table 137. Yantai Dongcheng Basic Information, Area Served and Competitors
Table 138. Yantai Dongcheng Major Business
Table 139. Yantai Dongcheng Targeted Radionuclide Drug Product and Services
Table 140. Yantai Dongcheng Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 141. Yantai Dongcheng Recent Developments/Updates
Table 142. Yantai Dongcheng Competitive Strengths & Weaknesses
Table 143. Grand Pharma Basic Information, Area Served and Competitors

Table 144. Grand Pharma Major Business
Table 145. Grand Pharma Targeted Radionuclide Drug Product and Services
Table 146. Grand Pharma Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 147. Grand Pharma Recent Developments/Updates
Table 148. Grand Pharma Competitive Strengths & Weaknesses
Table 149. Hengrui Medicine Basic Information, Area Served and Competitors
Table 150. Hengrui Medicine Major Business
Table 151. Hengrui Medicine Targeted Radionuclide Drug Product and Services
Table 152. Hengrui Medicine Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 153. Hengrui Medicine Recent Developments/Updates
Table 154. Hengrui Medicine Competitive Strengths & Weaknesses
Table 155. Yunnan Baiyao Group Basic Information, Area Served and Competitors
Table 156. Yunnan Baiyao Group Major Business
Table 157. Yunnan Baiyao Group Targeted Radionuclide Drug Product and Services
Table 158. Yunnan Baiyao Group Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 159. Yunnan Baiyao Group Recent Developments/Updates
Table 160. Yunnan Baiyao Group Competitive Strengths & Weaknesses
Table 161. SmartNuclide Biopharma Basic Information, Area Served and Competitors
Table 162. SmartNuclide Biopharma Major Business
Table 163. SmartNuclide Biopharma Targeted Radionuclide Drug Product and Services
Table 164. SmartNuclide Biopharma Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 165. SmartNuclide Biopharma Recent Developments/Updates
Table 166. SmartNuclide Biopharma Competitive Strengths & Weaknesses
Table 167. Sinotau Basic Information, Area Served and Competitors
Table 168. Sinotau Major Business
Table 169. Sinotau Targeted Radionuclide Drug Product and Services
Table 170. Sinotau Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 171. Sinotau Recent Developments/Updates
Table 172. Hexin Pharmaceutical Basic Information, Area Served and Competitors
Table 173. Hexin Pharmaceutical Major Business
Table 174. Hexin Pharmaceutical Targeted Radionuclide Drug Product and Services
Table 175. Hexin Pharmaceutical Targeted Radionuclide Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 176. Global Key Players of Targeted Radionuclide Drug Upstream (Raw

Materials)

Table 177. Targeted Radionuclide Drug Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. Targeted Radionuclide Drug Picture

Figure 2. World Targeted Radionuclide Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Targeted Radionuclide Drug Total Market Size (2018-2029) & (USD Million)

Figure 4. World Targeted Radionuclide Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Targeted Radionuclide Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Targeted Radionuclide Drug Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Targeted Radionuclide Drug Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Targeted Radionuclide Drug Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Targeted Radionuclide Drug Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Targeted Radionuclide Drug Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Targeted Radionuclide Drug Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Targeted Radionuclide Drug Revenue (2018-2029) & (USD Million)

Figure 13. Targeted Radionuclide Drug Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Targeted Radionuclide Drug Consumption Value (2018-2029) & (USD Million)

Figure 16. World Targeted Radionuclide Drug Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Targeted Radionuclide Drug Consumption Value (2018-2029) & (USD Million)

Figure 18. China Targeted Radionuclide Drug Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Targeted Radionuclide Drug Consumption Value (2018-2029) & (USD Million)



Figure 20. Japan Targeted Radionuclide Drug Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Targeted Radionuclide Drug Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Targeted Radionuclide Drug Consumption Value (2018-2029) & (USD Million)

Figure 23. India Targeted Radionuclide Drug Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Targeted Radionuclide Drug by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Targeted Radionuclide Drug Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Targeted Radionuclide Drug Markets in 2022

Figure 27. United States VS China: Targeted Radionuclide Drug Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Targeted Radionuclide Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Targeted Radionuclide Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Targeted Radionuclide Drug Market Size Market Share by Type in 2022

Figure 31. Medicine

Figure 32. Inhibitor

Figure 33. World Targeted Radionuclide Drug Market Size Market Share by Type (2018-2029)

Figure 34. World Targeted Radionuclide Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 35. World Targeted Radionuclide Drug Market Size Market Share by Application in 2022

Figure 36. Tumors

Figure 37. Thyroid

Figure 38. Others

Figure 39. Targeted Radionuclide Drug Industrial Chain

Figure 40. Methodology

Figure 41. Research Process and Data Source

## I would like to order

Product name: Global Targeted Radionuclide Drug Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G1650F73B5DBEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1650F73B5DBEN.html>